Dutasteride Capsule
NDC Package 84091-100-90

11-digit billing NDC: 84091010090

Package Information

Dutasteride capsules is dutasteride is contraindicated for use in:Pregnancy. This formulation utilizes a capsule delivery system. Marketed by Banyan Pharma Llc, this product is identified by NDC 84091-100 and is authorized under FDA application ANDA204705.

Identification & Billing

NDC Package Code
84091-100-90
Package Description
90 CAPSULE in 1 BOTTLE
Product Code
11-Digit Billing Format
84091010090
RxNorm Crosswalk
RxCUI: 351172 - dutasteride 0.5 MG Oral Capsule

Clinical Specifications

Proprietary Name
Dutasteride
Non-Proprietary Name
Dutasteride
Substance Name
Dutasteride
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Dutasteride is contraindicated for use in:Pregnancy. In animal reproduction and developmental toxicity trials, dutasteride inhibited development of male fetus external genitalia. Therefore, dutasteride may cause fetal harm when administered to a pregnant woman. If dutasteride is used during pregnancy or if the patient becomes pregnant while taking dutasteride, the patient should be apprised of the potential hazard to the fetus [see Warnings and Precautions (5.4), Use in Specific Populations (8.1)].Women of childbearing potential [see Warnings and Precautions (5.4), Use in Specific Populations (8.1)].Pediatric patients [see Use in Specific Populations (8.4)].Patients with previously demonstrated clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride or other 5 alpha-reductase inhibitors [see Adverse Reactions (6.2)].

Regulatory & Marketing

Labeler Name
Banyan Pharma Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA204705
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-31-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 84091-100-90 identifies a specific commercial package of 90 capsule in 1 bottle of Dutasteride, a human prescription drug labeled by Banyan Pharma Llc. This capsule is formulated for oral use and contains dutasteride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Banyan Pharma Llc on December 31, 2025. The current certification is valid through December 31, 2027.

How is this Banyan Pharma Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 84091010090. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
84091-100-90
11-Digit CMS (5-4-2)
84091-0100-90

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.